Source-grounded facts extracted from Medtronic plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Medtronic plc reported financial results for fourth quarter (Q4) and fiscal year 2026 (FY26), which ended April 24, 2026.
“On June 03, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter and fiscal year 2026 financial results.”
Kweli Thompson changed role as Executive Vice President and President, Neuroscience Portfolio at Medtronic plc.
“Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026.”
Brett Wall departed as Executive Vice President and President, Neuroscience Portfolio at Medtronic plc.
“Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio”
Medtronic plc: Amendments to Articles of Association to authorize capitalization of non-distributable reserves and update advance notice provisions (effective 2025-10-16).
“The amendments (i) make certain clarificatory modifications to Article 177 to authorize the Board of Directors to capitalize certain of the Company’s non-distributable reserves to facilitate the creation of additional distributable reserves (Proposal 7); and (ii) update the Company’s advance notice provisions (Proposal 9).”
Dr. Joon Lee was appointed as Director at Medtronic plc.
“On June 18, 2025, the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director of the Company, in each case effective as of June 18, 2025.”
Skip Kiil was appointed as EVP and President, Cardiovascular Portfolio at Medtronic plc.
“Skip Kiil would be assuming the role of EVP and President, Cardiovascular Portfolio”
Sean Salmon departed as EVP and President, Cardiovascular Portfolio at Medtronic plc.
“Sean Salmon would be departing from his position as EVP and President, Cardiovascular Portfolio”
Denise L. Blomquist was appointed as Global Controller and Principal Accounting Officer at Medtronic plc.
“The Company has appointed Denise L. Blomquist, currently the Company's Assistant Global Controller, to succeed Ms. Kirk as the Company's Global Controller and Principal Accounting Officer, effective March 17, 2025.”
Jennifer M. Kirk resigned as Global Controller and Principal Accounting Officer at Medtronic plc.
“On March 12, 2025, Jennifer M. Kirk, the Global Controller and Principal Accounting Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective May 2, 2025, to become the chief executive officer of Exubrion Therapeutics, a privately held company.”
Thierry Pieton was appointed as Executive Vice President and Chief Financial Officer at Medtronic plc.
“On January 21, 2025, Medtronic plc (Company) announced the appointment of Thierry Pieton, age 54, as the Company’s Executive Vice President and Chief Financial Officer (CFO), effective as of March 3, 2025 (Effective Date).”
Gary Corona was appointed as interim Chief Financial Officer at Medtronic plc.
“On June 26, 2024, the Company announced that Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, has been appointed to serve as interim Chief Financial Officer (Interim CFO) of the Company, effective upon Ms. Parkhill’s departure.”
Karen L. Parkhill resigned as Executive Vice President and Chief Financial Officer at Medtronic plc.
“On June 21, 2024, Karen L. Parkhill, Executive Vice President and Chief Financial Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective August 2, 2024.”
Rob ten Hoedt retired as Executive Vice President and President, Global Regions at Medtronic plc.
“On June 1, 2024, Rob ten Hoedt, Executive Vice President and President, Global Regions of Medtronic plc (Company), notified the Company of his decision to retire from the Company, effective as of June 28, 2024.”
Medtronic plc reported third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 results: revenue $8.1 billion, net income $1.322 billion, EPS $0.99. Guidance raised.
“Revenue of $8.1 billion increased 4.7% as reported and 4.6% organic • GAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.30 • Raises FY24 organic revenue growth and EPS guidance”
Robert J. White departed as Executive Vice President and President of Medtronic’s Medical Surgical Portfolio at Medtronic plc.
“Mr. White will leave the Company effective April 26, 2024, and because Mr. White’s separation from Medtronic constitutes a termination without cause, Mr. White will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers, as described in Medtronic’s 2023 Proxy Statement filed with the Securities and Exchange Commission on August 11, 2023.”
Medtronic plc reported second quarter of fiscal year 2024 results: revenue Revenue of $8.0 billion. Guidance raised.
“2023 – Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights • Revenue of $8.0 billion increased 5.3% as reported and 5.0% organic • GAAP diluted earnings per share (EPS) of $0.68; non-GAAP diluted EPS of $1.25 • Underlying business fundamentals are strong with”
Medtronic plc shareholders approved Authorize overseas market purchases of ordinary shares at the 2023-10-19 meeting.
“7. The shareholders approved authorization of the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. FOR AGAINST ABSTAIN 1,107,883,517 52,096,146 4,187,303”
Medtronic plc shareholders approved Renew Board's authority to opt out of pre-emption rights at the 2023-10-19 meeting.
“6. The shareholders approved renewal of the Board’s authority to opt out of pre-emption rights. FOR AGAINST ABSTAIN 1,090,829,831 70,342,442 2,994,693”
Medtronic plc shareholders approved Renew Board's authority to issue shares at the 2023-10-19 meeting.
“5. The shareholders approved renewal of the Board’s authority to issue shares. FOR AGAINST ABSTAIN 1,145,356,737 16,259,098 2,551,131”
Medtronic plc shareholders approved Approve 2024 Employee Stock Purchase Plan at the 2023-10-19 meeting.
“4. The shareholders approved the Company's 2024 Employee Stock Purchase Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 1,033,704,001 3,320,010 4,586,233 122,556,722”
Medtronic plc shareholders approved Non-binding advisory vote on named executive officer compensation at the 2023-10-19 meeting.
“3. The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 968,139,099 68,905,223 4,565,922 122,556,722”
Medtronic plc shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent auditor and authorize Board to set remuneration at the 2023-10-19 meeting.
“2. The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2024 and authorized, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration. FOR AGAINST ABSTAIN 1,060,656,333 101,691,327 1,819,306”
Medtronic plc shareholders approved Election of eleven directors to hold office until the 2024 Annual General Meeting at the 2023-10-19 meeting.
“1. The shareholders elected each of the eleven nominees to the Board of Directors, to hold office until the 2024 Annual General Meeting of the Company and until his or her successor is elected, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE Craig Arnold 1,015,233,892 25,512,208 864,144 122,556,722”
Medtronic plc reported first quarter of fiscal year 2024 (FY24), which ended July 28, 2023 results: revenue $7.702 billion, net income $791 million, EPS $0.59. Guidance raised.
“Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2024 (FY24), which ended July 28, 2023. Key Highlights • Revenue of $7.7 billion increased 4.5% as reported and 6.0% organic • GAAP diluted earnings per share (EPS) of $0.59 decreased 16%; non-GAAP diluted EPS of $1.20 increased 6% • Company increases FY24 organic revenue growth and EPS guidance”
Greg Lewis was appointed as Director at Medtronic plc.
“appointed Greg Lewis as a new director of the Company”
Medtronic plc reported fiscal year 2023 results: revenue $31.227 billion, net income $3.758 billion, EPS $2.82.
“non-GAAP diluted EPS were $2.093 billion and $1.57, respectively, both increases of 3%. Fiscal Year 2023 (FY23) Financial Results Medtronic reported FY23 worldwide revenue of $31.227 billion, a decrease of 1.4% as reported and an increase of 2.1% on an organic basis. The FY23 organic revenue growth comparison excludes: • a $1.437 billion negative impact from foreign”
Medtronic plc reported fourth quarter fiscal year 2023 results: revenue $8.5 billion, net income $1.179 billion, EPS $0.88.
“Q4 revenue of $8.5 billion increased 5.6% as reported and organic, ahead of expectations • Q4 GAAP diluted EPS of $0.88 decreased 20%; non-GAAP diluted EPS of $1.57 increased 3% in the quarter, ahead of expectations”
Medtronic plc entered into Seventh Supplemental Indenture with Computershare Trust Company, N.A., as trustee valued at $1,000,000,000 aggregate principal amount of its 4.250% Senior Notes due 2028 and $1,000,000,000 agg (effective 2023-03-30).
“The Seventh Supplemental Indenture dated as of March 30, 2023 (the “Seventh Supplemental Indenture” and together with the Sixth Supplemental Indenture and the Base Indenture, the “Indenture”) among Medtronic Luxco, Medtronic, Inc., Medtronic plc and the Trustee.”
Medtronic plc reported third quarter fiscal year 2023 ended January 27, 2023 results: revenue $7.727 billion, net income $1.222 billion (GAAP); $1.727 billion (non-GAAP), EPS $0.92 (GAAP diluted); $1.30 (non-GAAP diluted). Guidance raised.
“Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN – Feb. 21, 2023 – Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights • Revenue of $7.7 billion was flat as reported and increased 4.1% organic, ahead of expectations • GAAP diluted EPS of $0.92 decreased 16%; non-GAAP diluted EPS of $1.30 decreased 4%, ahead of expectations • Company increases FY23 organic revenue growth and EPS outlook”
Medtronic plc shareholders approved Authorization of overseas market purchases of Medtronic ordinary shares by Company and subsidiaries at the 2022-12-08 meeting.
“6. The shareholders approved authorization of the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. FOR AGAINST ABSTAIN 1,129,189,149 27,068,953 4,163,131”
Medtronic plc shareholders approved Renewal of Board's authority to opt out of pre-emption rights at the 2022-12-08 meeting.
“5. The shareholders approved renewal of the Board’s authority to opt out of pre-emption rights. FOR AGAINST ABSTAIN 1,136,000,204 21,877,612 2,543,417”
Medtronic plc shareholders approved Renewal of Board's authority to issue shares at the 2022-12-08 meeting.
“4. The shareholders approved renewal of the Board’s authority to issue shares. FOR AGAINST ABSTAIN 1,146,144,000 11,969,471 2,307,762”
Medtronic plc shareholders approved Advisory vote on named executive officer compensation at the 2022-12-08 meeting.
“3. The shareholders approved, on a non-binding advisory basis, the compensation awarded to the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTE 972,415,707 69,940,489 2,116,068 115,948,969”
Medtronic plc shareholders approved Ratify appointment of PricewaterhouseCoopers LLP as independent auditor and authorize Board to set remuneration at the 2022-12-08 meeting.
“2. The shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2023 and authorized, in a binding vote, the Company’s Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration. FOR AGAINST ABSTAIN 1,069,480,945 89,379,651 1,560,637”
Medtronic plc shareholders approved Election of eleven directors to hold office until 2023 Annual General Meeting at the 2022-12-08 meeting.
“1. The shareholders elected each of the eleven nominees to the Board of Directors, to hold office until the 2023 Annual General Meeting of the Company and until his or her successor is elected, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE Richard H. Anderson 982,165,958 61,475,254 831,052 115,948,969 Craig Arnold 1,006,424,719 28,982,687 9,064,858 115,948,969 Scott C. Donnelly 1,023,458,233 20,095,049 918,982 115,948,969 Lidia L. Fonseca 1,027,825,711 15,881,098 765,455 115,948,969 Andrea J. Goldsmith, Ph.D. 1,040,386,088 3,158,654 927,522 115,948,969 Randall J. Hogan, III 1,034,757,456 8,853,730 861,078 115,948,969 Kevin E. Lofton 1,040,312,283 3,322,096 837,885 115,948,969 Geoffrey S. Martha 966,120,676 71,626,975 6,724,613 115,948,969 Elizabeth G. Nabel, M.D. 910,568,825 133,144,537 758,902 115,948,969 Denise M. O’Leary 953,636,260 89,936,614 899,390 115,948,969 Kendall J. Powell 939,339,071 104,313,760 819,433 115,948,969”
Medtronic plc reported second quarter of fiscal year 2023, which ended October 28, 2022 results: revenue $7.585 billion, net income $427 million, EPS $0.32.
“Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022. Key Highlights • Revenue of $7.6 billion decreased 3% as reported and increased 2% organic • GAAP diluted EPS of $0.32 decreased 67%; non-GAAP diluted EPS of $1.30 decreased 2% • Company updates guidance; expects organic revenue to accelerate in second half”
Lidia L. Fonseca was appointed as Director at Medtronic plc.
“the Board of Directors (Board) of Medtronic plc (Company) increased the size of the Board from 10 to 11 and appointed Lidia L. Fonseca as a new director of the Company, in each case effective as of June 27, 2022.”
Richard Kuntz retired as Senior Vice President and Chief Medical and Scientific Officer at Medtronic plc.
“On December 14, 2021, Richard Kuntz, M.D. notified Medtronic plc (the “Company”) that he had decided to retire as Senior Vice President and Chief Medical and Scientific Officer of the Company, effective as of April 29, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.